Center for Biosimilars

Real-World Natalizumab Biosimilar Switch Reduced Treatment Satisfaction Despite Stable Outcomes

Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, ...
centerforbiosimilars

Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences

A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences. A romosozumab biosimilar in late-stage ...
centerforbiosimilars

Tyler Sandahl, PharmD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Paul Cornes, BM, BCH, MA, MRCP, FRCR

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

April Breyer Menon, JD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Peter Pitts

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

James D. Chambers, PhD, MPharm, MSc

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Saro Arakelians, PharmD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

St John Skilton, PhD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

John Bujnoski

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Corey Greenblatt, MPH

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...